Conference Proceedings
Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Peter Borchmann, Ulrich Jaeger, Edmund K Waller, Harald Holte, Joseph McGuirk, Samantha Jaglowski, Kensei Tobinai, Charalambos Andreadis, Isabelle Fleury, Stephan Mielke, Takanori Teshima, Jason R Westin, Veronika Bachanova, Stephen Ronan Foley, Joy Ho, John M Magenau, Nina Wagner-Johnston Show all
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | ELSEVIER SCIENCE INC | Published : 2019
Abstract
Background Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, has demonstrated efficacy and manageable safety in adult patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in the global, multicenter, pivotal, phase 2, JULIET trial (NCT02445248). The primary endpoint, overall response rate (ORR), was met at the interim analysis (ORR: 59% [CR, 43%; PR, 16%]). Here, we report an updated analysis with a median 19 mo follow-up. Methods Adult pts ≥18 y with r/r DLBCL that had progressed after ≥2 lines of therapy including rituximab and an anthracycline and who were ineligible for or failed autologous stem cell transplant (ASCT) were enrolled. Tisagenlecleuce..
View full abstract